The evaluated GLP-1RAs were semaglutide (IC 025 = 2.13), liraglutide (IC 025 = 1.18), dulaglutide (IC 025 = 3.76), exenatide (IC 025 = 3.52), and albiglutide (IC 025 = 3.91), none of which exhibited a signal of disproportionate reporting
More recently, interest has expanded to newer GLP-1 medications such as semaglutide and liraglutide
MT-1s selectivity for MC1R over MC3R, MC4R, and MC5R distinguishes it from Melanotan 2, which has broader receptor activity
Food and Drug Administration requires Novo Nordisk to add warnings to Ozempic that the semaglutide may cause serious gastrointestinal issues such as intestinal blockage and ileus
Prescription and telehealth included
Drink approximately eight glasses of water each day